LONDON – The EMA has again diverged from the FDA on its view of risk vs. benefit, giving a second negative opinion for Portola Pharmaceuticals Inc.'s Bevyxxa (betrixaban) for the prevention of venous thromboembolism and for Radius Health Inc.'s Tymlos (abaloparatide) for osteoporosis, both of which received U.S. approval last year.